Silo Pharma (NASDAQ: SILO) announced that its wholly owned subsidiary, QwikAgents, has been accepted into Advanced Micro Devices’ (AMD) AI Developer Program. This membership provides QwikAgents with access to AMD Developer Cloud credits, AI development tools, training resources, and a global developer community. The company stated that the program is expected to accelerate development, testing, optimization, and deployment of its AI agent platform across consumer and enterprise applications.
QwikAgents is developing a platform that enables users to deploy persistent AI agents for tasks including research, content generation, scheduling, coding, and workflow automation. Silo said participation in the AMD AI Developer Program is expected to support platform performance, agent reliability, and scalable deployment as QwikAgents expands its capabilities for individuals, developers, small businesses, and enterprise customers.
This announcement marks a strategic move for Silo Pharma, which is a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company. Its therapeutic focus is on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The company’s portfolio includes innovative programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer’s disease and multiple sclerosis. Silo’s research is conducted in collaboration with leading universities and laboratories.
Investors can view the full press release at https://ibn.fm/313SC. For the latest news and updates relating to SILO, visit the company’s newsroom at https://ibn.fm/SILO.
The AMD AI Developer Program is designed to help developers integrate AMD’s AI technologies into their solutions. For QwikAgents, this means leveraging AMD’s hardware and software ecosystem to optimize its AI agents. The platform’s persistent agents are intended to handle repetitive tasks autonomously, potentially improving productivity for users across various sectors.
Silo Pharma’s involvement with AMD highlights the convergence of biotech and AI technologies. While Silo’s primary focus remains on biopharmaceuticals, the QwikAgents subsidiary represents a diversification into AI-driven software. This move could provide additional revenue streams and technological synergies.
